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Induction of CYP2El activity in liver 
transplant patients as measured by 
chlorzoxazone 6-hydroxylation 
Objectifle: To examine the phenotypic expression of C¥P2EI in liver transplant patients, as measured by 
the in vivo probe chlorzoxazone, and to evaluate C¥P2EI activity over time after transplantation. 
Methods: Thirty-three stable liver transplant patients were given 250 mg chlorzoxazone within 1 year after 
transplantation as part of a multiprobe CYP cocktail; urine and blood were collected for 8 hours. 
Chlorzoxazone and 6-hydroxychlorzoxazone concentrations were determined by HPLC. Twenty-eight 
healthy control subjects, eight patients with moderate to severe liver disease, and four patients who had not 
received liver transplants were also studied for comparison. The chlorzoxazone metabolic ratio, calculated 
as the plasma concentration of 6-hydroxychlorzoxazone/chlorzoxazone at 4 hours after chlorzoxazone 
administration, was used as the phenotypic index. In a subgroup of patients and control subjects, addi-
tional blood samples were obtained to allow for the calculation of chlorzoxazone pharmacokinetic param-
eters by noncompartmental methods. 
Results: The chlorzoxazone metabolic ratio for the liver transplant patients in the first month after 
transplantation (mean ± SD, 6.4 ± 5.1) was significantly higher than that after 1 month after surgery 
(2.1 ± 2.0), when the chlorzoxazone metabolic ratio was not different from control subjects (0.8 ± 
0.5). The chlorzoxazone metabolic ratios in the patients who had not received liver transplants (1.1 ± 
0.7) were equivalent to those of healthy control subjects. The maximum observed 
6-hydroxychlorzoxazone plasma concentration was 3046 ± 1848 ng/ml in seven liver transplant 
patients in the first month after surgery compared with 1618 ± 320 ng/ml in 16 healthy control 
subjects (p < 0.05). The maximum observed concentration of chlorzoxazone, the chlorzoxazone 
apparent oral clearance, and the formation clearance of 6-hydroxychlorzoxazone were also signifi-
cantly different between the groups. 
Conclusions: We conclude that significant induction of C¥P2EI, as indicated by the chlorzoxazone met-
abolic ratio, occurs in the first month after sugery in liver transplant patients and that drugs that are 
substrates for CYP2El may require dosage alteration during that period. Contrary to expectations, drug 
metabolism is not uniformly depressed after liver transplantation. (Clin Pharmacol Ther 1998;63:296-
302.) 
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Alterations in drug absorption, distribution, me-
tabolism, and urinary and biliary excretion have 
been documented at various times after organ trans-
plantation. 1 Drug metabolism in liver transplant pa-
tients is of particular concern because the liver is 
primarily responsible for the biotransformation of 
most xenobiotics. The procedure of transplanting a 
complete or partial liver from a donor to the recip-
ient involves a number of steps that ultimately affect 
drug metabolism. 'The process of preservation, reper-
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fusion injury, inflammatory changes associated 
with the surgical procedure. technical complica-
tions involving the flow of blood and bile, and the 
immunologic response of the recipient all produce 
complex effects that primarily or secondar:!y alter 
drug disposition. 
The cytochrome P450 enzymes (CYP) are primar-
ily responsible for the biotransformation of drugs, 
and more than 30 different human isoforms exist. 
The CYP isozyme 2E1 (CYP2El) is responsible for 
the bioactivation of many suspect carcinogenic com-
pounds including N-nitrosodimethylamine. aniline. 
chlorinated and fluorinated hydrocarbons, benzene, 
and N-alkylformides.2•5 CYP2El is also important 
in the metabolism of alcohol and pharmacologic 
agents such as acetaminophen (INN. paracetamol) 
and isoniazid.6-7 Because the catalytic activity of 
CYP2El may be an important modulator of the 
toxicity or carcinogenicity of these compounds, non-
invasive methods to estimate the in vivo activity of 
this enzyme in humans have been proposed.8-9 
Chlorzoxazone is a centrally acting skeletal mus-
cle relaxant that primarily undergoes hydro;.;yla-
tion to form 6-hydroxychlorzoxazone. This oxida-
tive reaction has been shown in vitro to be 
catalyzed by CYP2El. \0 Although CYPIAI may 
also be involved in the 6-hydroxylation of the 
drug. many factors support chlorzoxazone as a 
probe of CYP2E 1 activity. It The use of chlorzoxa-
zone as a phenotypic probe has been applied in 
various populations. 12 
Previous work in our group had indicated that 
CYP2El activity, as measured by the 6-hydroxylation 
of chlorzoxazone. was reduced in the presence of mod-
erate to severe liver disease.13 Whether these same 
changes would be observed in patients whose liver had 
received the preservation and surgical challenge of the 
liver transplant operation was unknown. The initial 
hypothesis related to the CYP eI1Z!mes and liver trans-
plantation was that all of the isozymes would initially 
have depressed function caused by ischemic and in-
flammatory changes, but that a differential recovery of 
CYP function should be observed. This study was 
undertaken to examine whether changes occur in the 
phenotypic expression of CYP2E 1 after I iver trans-
plantation as measured by the in vivo probe chlorzoxa-
zone and to examine the time course of normalization 
if changes did occur. 
:\lETHODS 
ii~Der transplant patients. This study was approved 
tw the Biomedical Institutional Review Board of the 
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University of Pittsburgh, and all patients undergoing 
orthotopic liver transplantation at the University of 
Pittsburgh Medical Center were considered to be 
eligible for study participation. The transplant pro-
cedure has been described in detail previousl/ 4 and 
the anesthetic used in these patients was primarily 
isoflurane. Patients were studied only during periods 
in which they were considered to be clinically stable. 
Patients were excluded from the study if they were 
receiving agents known to produce significant-1~K:- ' 
tion (anticonvulsants or rifampin [INN, rifampicin]) 
or inhibition (ketoconazole. fluconazole, cimetidine. 
or erythromycin) of CYP enzymes or if they had an , 
estimated creatinine clearance 15 of less than 50 mU 
min. Although multiple studies were not possible in 
all patients. attempts were made to study the sub-
jects in the early posttransplant period (1 to 2 
weeks), 1 to 4 months after transplant. and during 
long-term follow-up (6 to 12 months). 
Patients who had not receired li~Der transplants. To 
control for the concurrent administration of im-
munomodulating agents, kidney or heart trans-
plant patients who were receiving the same immu-
nosuppressive regimen as the liver transplant 
patients were recruited for study. The anesthetic 
used for these procedures was primarily isoflu-
rane. As in the case of the liver transplant pa-
tients. these subjects were required to be clinically 
stable, to not be taking any known interacting 
medication. and to have an estimated creatinine 
clearance of greater than 50 ml/min. 
Normal subjects and patients with li~Der disease. 
Eight patients with moderate (n = 5) or severe (n = 
3) liver disease and 28 healthy control subjects par-
ticipated after giving written informed consent. Pa-
tients with liver disease were classified with the 
Child-Pugh score. 16 Subjects were instructed to ab-
stain from caffeine- or alcohol-containing products 
for at least 3 days before each study visit. 
Study protocol. After an overnight fast. subjects 
received 250 mg chlorzoxazone as part of an oral 
multiprobe cocktail that also included 100 mg caf-
feine. 100 rng dapsone. 100 mg mephenytoin. and 10 
mg debrisoquin (INN. debrisoquine). None of the 
five agents given in this cocktail influences the me-
taboli~m of~ the other agents given concurrently.17 
The five drugs were taken simultaneously with ap-
proximately 240 ml water. Venous blood was col-
lected through an indwellmg catheter before and at 
4 and 8 hours after drug administration. In some 
liver transplant patients (II = 7) and healthy control 
subjects (1/ = 16), hlood samples were obtained 
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Table I. Patient demographics from each of the study groups 
Health\' control Patients I\'ith Patients who had not Lh'er transplant 
subjects li~Der disease receil'l?d liver transplants patients 
n 28 8 4 30 
Age (yr) 33.9 :: 17.1 51.8:: 16.1 49.9:: 17.1 49.2 :: ll.5 
Gender 
Male 26 6 3 21 
Female 2 2 1 9 
Weight (kg) 80.6:: 16.1 85.8:: 24.9 77.7:: 16.9 82.2:: 18.9 
CLCR (mVmin) 109.8:: 34.6 90.1:: 29.5 62.5 ± 11.5 77.8 ± 31.7 
Postoperative days (range) 
CLcR' Creatinine clearance. 
before and at 2, 4, 6, 8, and 12 hours after drug 
administration. Plasma was harvested and stored at 
-200 C until analysis. Urine was collected before 
drug administration and for 8 hours after. The total 
volume was recorded and an aliquot was stored at 
-200 C until analyzed. 
Sample a1llllysis. Concentrations of chlorzoxazone 
and 6-hydroxychlorzoxazone in plasma and 
6-hydroxychlorzoxazone in urine were measured 
with use of a reversed-phase HPLC procedure de-
scribed previously.18 The within- and between-day 
coefficients of variation of this assay are less than 
10%. Serum and 8-hour urine creatinine determina-
tions provided the basis for the calculation of mea-
sured creatinine clearance in each subject. 
Data analysis. Subjects were excluded from anal-
ysis if they had a measured creatinine clearance of 
less than 40 mUmin. The activity of CYP2El was 
estimated with the ratio of 6-hydroxychlorzoxazone 
to chlorzoxazone in the 4-hour plasma sample 
(chlorzoxazone metabolic ratio). In those patients in 
whom more blood samples were obtained, addi-
tional chlorzoxazone pharmacokinetic parameters 
were calculated by noncompartmental methods. 
The elimination rate constant and half-life were 
obtained by nonlinear least-squares regression of 
the terminal concentration-time data. The area un-
der-thi~""Concentration versus time curve (AUC) was 
calculated by the trapezoidal rule with extrapolation 
to infinity. The apparent oral clearance of chi or-
zoxazone was determined as follows: Dose/ 
AUC(O-x). The total urinary recovery of 6-hydroxy-
chlorzoxazone was determined. and the formation 
clearance was calculated as the total amount recov-
ered in urine divided by the chlorzoxazone plasma 
AVC over the same period. 
Statistical analysis. The metabolic ratios were 
compared between all groups by ANOV A. Chlor-
10-161 7-336 
zoxazone pharmacokinetic parameter estimates in 
liver transplant patients and healthy control subjects 
were compared by t test. Differences were consid-
ered statistically significant whenp :5 0.05. Relation-
ships between the chlorzoxazone metabolic ratio 
and selected patient variables were assessed by lin-
ear regression analysis. All calculations were per-
formed with use of SAS Software, version 6.11 
(SAS, Cary, N.C.). 
RESULTS 
Thirty-three liver transplant patients were en-
rolled in this study; one patient was studied on five 
separate occasions, two patients were studied four 
times, three patients were studied three times, eight 
patients were studied twice, and 19 patients were 
studied one time. Even though all subjects had an 
estimated creatinine clearance of greater than 50 
mVmin, nine patient studies had to be excluded from 
analysis because the measured creatinine clearance 
was less than 40 m\fmin, which eliminated three 
patients from the final analysis. Four patients who 
had not received liver transplants were studied on 
five occasions, two kidney transplant patients were 
studied at 10 and 20 days after surgery, and two 
heart transplant patients were studied (one at 24 
days, and one at 102 and 161 days after surgery). 
The demographics of the subjects who were in-
cluded in the analysis are presented in Table I. 
The chlorzoxazone metabolic ratios of the liver 
transplant patients were significantly elevated in the 
first month after liver transplantation compared 
with healthy control subjects, patients with liver dis-
ease. and the patients who had not received liver 
transplants (Fig. 1). This elevated ratio gradually 
declined over the subsequent months to values sim-
ilar to those observed in normal volunteers (Fig. 2). 
Sequential studies for the liver transplant patients 
-
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Fig. 1. The 4-hour chlorzoxazone metabolic ratio in the 
five study populations: liver transplant patients in the first 
month after transplantation (OLTX-Early), liver trans-
plant p<ltient studies beyond one month after transplan-
tation (OLTX-Late), patients who had not received liver 
transplants (Non-Liver TX). patients with liver disease, 
and healthy control subjects. Only the OL TX-EarJy pa-
tients were significantly different from the other groups by 
ANOYA. 
with at least three studies after the elimination of 
the renally impaired subjects are shown in Fig. 3. 
The 8-hour urinary recovery of 6-hydroxychlorzoxa-
zone did not change significantly over time when 
plotted against days after liver transplant (r = -0.19, 
p = 0.21). 
The concentration versus time profile of chlor-
zoxazone and 6-hydroxychlorzoxazone were mark-
edly different in liver transplant patients in the first 
postoperative month compared with healthy control 
subjects (Fig. 4). In the liver transplant patients. 
6-hydroxychlorzoxazone concentrations exceeded 
the chlorzoxazone concentrations at all time points, 
whereas this did not occur in normal volunteers. The 
kinetic parameters calculated for the seven liver 
transplant patients and for the 16 healthy control 
subjects are presented in Table II. 
No significant relationship was observed between 
the chlorzoxazone metabolic ratio and the daily mil-
ligram per kilogram dose of tacrolimus (r = 0.10; 
not significant), but a weak correlation was found 
with the milligram dosage of prednisone (r = 0.33; 
p = 0.04). The chlorzoxazone metabolic ratio was 
significantly correlated with the serum biochemical 
markers -y-glutamyltransferase (r = 0.37;p = 0.014). 
bilirubin (r = 0.76: p < 0.001), and ALT (r = 0.31: 
p = 0.038) but did not correlate with AST (r = 0.06: 
not significan t). 
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Fig. 2. The 4-hour chlorzoxazone metabolic ratio versus 
days after transplantation in the liver transplant patients 
(r = -0.56; p < 0.001). 
DISCUSSION 
The ratio of 6-hydroxychlorzoxazone to chlor-
zoxazone was markedly elevated in liver transplant 
patients in the first month after transplantation. The 
higher chlorzoxazone metabolic ratio implies that 
CYP2E1 activity is enhanced in these patients and 
its subsequent decline indicates that the enzyme 
activity returns to values comparable to those ob-
served in healthy control subjects over time. 
A number of factors that are altered after liver 
transplantation were examined in relation to the 
alteration of the chlorzoxazone metabolic ratio. The 
fact that the chlorzoxazone metabolic ratio is signif-
icantly depressed in the patients with liver disease 
compared with the normal healthy subjects indicates 
that hepatocellular or biliary disease by itself does 
not produce an elevation in the chlorzoxazone met-
abolic ratio. The operative procedure probably did 
not produce this elevation in CYP2El activity, and 
biliary ligation in an animal model leads to a down-
regulation of CYP2E 1 activity. 19 No elevation in the 
chlorzoxazone metabolic ratio was observed in pa-
tients who had not received liver transplants who 
were also given the same immunosuppressant 
agents. Although the anesthetic agent routinely used 
in transplant patients. a fluorinated hydrocarbon, is 
a substrate for CYP2El. the patients who had not 
received liver transplants also received this agent 
but did not have an increased chlorzoxazone meta-
bolic ratio. 
Cytokine induction during the early posttrans-
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Fig. 3. The 4-hour chlorzoxazone metabolic ratio versus days after transplantation in the five 
liver transplant subjects who were studied at least three times during their follow-up. Each 
patient is described by a separate set of symbols. 
plantation period is pronounced in liver transplant 
patients because of reperfusion injury, rejection. in-
fection, and the inflammatory responses that accom-
pany these pathologic processes. Recent studies 
have provided direct evidence for the induction of 
CYP2El by cytokines. Abdel-Razzak et a\.,20 stud-
ied the effects of cytokines on the CYP isozyme 
messenger ribonucleic acid (mRNA) expression in 
human hepatocyte cultures and found that the only 
isozyme that was induced in the presence of 
interleukin-4 was CYP2El. Tindberg et a\.,21 also 
found that CYP2El mRNA was induced up to sev-
enfold in rat brain cortical glial cell cultures that 
were--e.xposed to lipopolysaccharide or interleukin-
I [3. Therefore the induction of CYP2E 1 activity in 
liver transplant patients exposed to high levels of 
cytokines is a viable explanation for the results ob-
served in this study. 
Another possible cause of chlorzoxazone meta-
bolic ratio elevation could be the slower elimination 
of the 6-hydroxychlorzoxazone metabolite in the 
liver transplant patients. ~~ To exclude this variable, 
patients with diminished rcnal function who might 
have reduced renal elimination of the 6-hydrox)'-
chiorzoxazone conjugate were excluded from anal-
ysis. Because a large portion of the administered 
chlorzoxazone dose is not recovered in the urine. 
one could speculate that the 6-hydroxychlorzox-
azone metabolite may be secreted in bile. If biliary 
dysfunction reduced the amount of metabolite elim-
inated in the bile, thereby increasing plasma concen-
trations of 6-hydroxychlorzoxazone, we would have 
expected a higher urinary metabolite recovery when 
the chlorzoxazone metabolic ratio was higher. How-
ever, the urinary excretion of 6-hydroxychlorzox-
alOne did not significantly correlate with chlorzoxa-
zone metabolic ratio. number of days after 
transplant in the liver transplant patients, or serum 
bilirubin. In addition to the lack of association 
between chiorzoxazone metabolic ratio and 
6-hydroxychlorzoxazone urinary recovery, we did 
not observe a significant change over time in the 
8-hour urinary rccovery of 6-hydroxychlorzoxazone 
in the liver transplant patients. 
The findings of this study are significant both to 
the understanding of the regulation of CYP-
mediated enzymatic degradation of endogenous 
and exogenous substrates and for the practical 
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Table II. Chlorzoxazone and 6-hydroxychlorzoxazone 
pharmacokinetic parameters in liver transplant 
patients \\ithin the first postoperative month and in 
healthy control subjects after single-dose 
administration of 250 mg chlorzoxazone 
Parameters 
Liver 
transplani 
patients 
(n = 7) 
Healthy control 
subjects 
In = 16) 
Chlorwl"a::one 
Plasma Cm ". 
(ng/ml) 
1440.1 :t: 912,7* 5321.5:t: 1439.8 
Plasma tl ~ (hr) 
cur (mL'min) 
6-Hydro.l)·chlorzoxa::one 
li rinary recovery 
(mg) 
1.7 :t: 1.0 
1181.7 :t: 908.3* 
172.6 :t: 21.0 
1.1 :t: 0.2 
~MTK4 :t: 220.1 
158.6 = 37.1 
Plasma Cm ... 
(ng/ml) 
3046.4:t: 1848.5* 1617.5 :!: 319.9 
Plasma tl~ (hr) 
elm (mVmin) 
2.1 :t: 0.5' 
1018.3 ::t 913.3* 
1.4 :t: 0.4 
263.1 ::t 163.1 
em .... Maximum concentration: t"2' half-life: CL F. apparent oral clear-
ance (in which F is the fraction absorbed); Cm. formation clearance. 
Data are mean values :: SO. 
'p < 0.05 versus healthy control subjects. 
applicability of this information to the manage-
ment of liver transplant patients. This study shows 
that CYP2El activity, as measured by the 
6-hydro:-;ylation of chlorzoxazone. can be mark-
edly elevated soon after liver transplantation. 
Other commonly studied isozymes of the CYP 
family are either depressed or unaltered during 
the early postoperative period. ~P-O~ The practical 
application of this study to liver transplant pa-
tients is that increased metabolic degradation of 
administered drugs that are metabolized by 
CYP2El may lead to either a diminished effect of 
the agent or to increased drug toxicity from a 
metabolite. Several of the fluorinated anesthetic 
agents. such as enflurane and sevoflurane. are 
metabolized by CYP2El, and some dosage alter-
ation may be necessary in a liver transplant pa-
tient who requires additional surgery in the early 
posttransplant period. CYP2El is also involved in 
the metabolism of acetaminophen. but our previ-
ous observations in 10 liver transplant patients did 
not find any change in drug elimination or conju-
gation compared with normal subjects.:;5 
In conclusion. this study has documented a 
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Fig. 4. The plasma concentration versus time profiles for 
the 16 healthy control subjects (A) and the seven liver 
transplant patients (B). The concentrations of 
6-hydroxychlorzoxazone (HCZX; broken line) and of the 
parent chlorzoxazone (CZX; solid line) are shown. The 
maximum observed concentrations and or3.1 clearances for 
chlorzoxazone and 6-hydrm;ychlorzoxazone were signifi-
cantly different in the two groups. 
markedly increased activity of CYP2El in the 
early postoperative period for liver transplant pa-
tients. as measured by the metabolic ratio of 6-
hydroxychlorzoxazone to chlorzoxazone in plasma 
at 4 hours after an oral dose of 250 mg chlorzoxa-
zone. The chlorzoxazonc metabolic ratio returned 
to values that were observed in normal subjects 
and the patients who had not received liver trans-
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plants between 1 month and 1 year after trans-
plantation. The definitive cause for this induction 
in CYP2E1 activity is currently unknown. The 
metabolic capacity of the individual CYP 
isozymes cannot be assumed to be uniformly de-
pressed in the postoperative period for liver trans-
plant patients, and alterations in drug regimens 
for substrates of CYP2El may be necessary for 
these patients. 
We acknowledge the excellent assistance of Terry 
McKaveney in the completion of multiple aspects of the 
study. 
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